Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Thumann, TA; Pferschy-Wenzig, E-M; Kumpitsch, C; Duller, S; Högenauer, C; Kump, P; Aziz-Kalbhenn, H; Ammar, RM; Rabini, S; Moissl-Eichinger, C; Bauer, R.
Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors.
Microbiol Spectr. 2024; 12(6):e0403123 Doi: 10.1128/spectrum.04031-23 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Constantini-Kump Patrizia

Duller Stefanie

Hoegenauer Christoph

Kumpitsch Christina Sarah

Moissl-Eichinger Christine

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

UNLABELLED: STW 5, a blend of nine medicinal plant extracts, exhibits promising efficacy in treating functional gastrointestinal disorders, notably irritable bowel syndrome (IBS). Nonetheless, its effects on the gastrointestinal microbiome and the role of microbiota on the conversion of its constituents are still largely unexplored. This study employed an experimental ex vivo model to investigate STW 5's differential effects on fecal microbial communities and metabolite production in samples from individuals with and without IBS. Using 560 fecal microcosms (IBS patients, n = 6; healthy controls, n = 10), we evaluated the influence of pre-digested STW 5 and controls on microbial and metabolite composition at time points 0, 0.5, 4, and 24 h. Our findings demonstrate the potential of this ex vivo platform to analyze herbal medicine turnover within 4 h with minimal microbiome shifts due to abiotic factors. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products, such as 18β-glycyrrhetinic acid, davidigenin, herniarin, 3-(3-hydroxyphenyl)propanoic acid, and 3-(2-hydroxy-4-methoxyphenyl)propanoic acid occurred. For davidigenin, 3-(3-hydroxyphenyl)propanoic acid and 18β-glycyrrhetinic acid, anti-inflammatory, cytoprotective, or spasmolytic activities have been previously described. Notably, the microbiome-driven metabolic transformation did not induce a global microbiome shift, and the detected metabolites were minimally linked to specific taxa. Observed biotransformations were independent of IBS diagnosis, suggesting potential benefits for IBS patients from biotransformation products of STW 5. IMPORTANCE: STW 5 is an herbal medicinal product with proven clinical efficacy in the treatment of functional gastrointestinal disorders, like functional dyspepsia and irritable bowel syndrome (IBS). The effects of STW 5 on fecal microbial communities and metabolite production effects have been studied in an experimental model with fecal samples from individuals with and without IBS. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products with reported anti-inflammatory, cytoprotective, or spasmolytic activities was observed, which may be relevant for the pharmacological activity of STW 5.

Find related publications in this database (using NLM MeSH Indexing)

Irritable Bowel Syndrome - microbiology, metabolism, drug therapy

Gastrointestinal Microbiome - drug effects

Humans - administration & dosage

Feces - microbiology

Biotransformation - administration & dosage

Adult - administration & dosage

Plant Extracts - metabolism, pharmacology

Male - administration & dosage

Female - administration & dosage

Bacteria - metabolism, classification, isolation & purification, drug effects, genetics

Middle Aged - administration & dosage

Plants, Medicinal - microbiology, chemistry

Find related publications in this database (Keywords)

STW 5

IBS

next-generation sequencing

microbiome

metabolomics

UHPLC-HRMS

© Med Uni Graz • Imprint